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Zoom lectures are no fun. Unless there’s participation from EVERYONE.
Objectives
● Discuss approach to Syphilis testing and management in persons infected with HIV and  HIV 
negative patients
● Review strategies to improve ART adherence
● Review ART options and considerations for initiating and modifying ART and clinically 
relevant Rx-Rx interactions
● Assess patients for HCV treatment and review simplified treatment strategies for patients with 
chronic HCV infection
22 yo M presents with CC: I think I have syphilis
What else do 
you want to 
know?
HPI/PMH
Patient had been lost to care  since 9/2019. 
Labs at that time:  HIV VL 124 , CD4 696 (38%).
Recently hospitalized 5/2020 and admitted to 
rehab for schizophreniform d/o, crystal meth 
use. Started on haldol, cogentin and sertraline 
and currently in outpatient psychiatric Tx 
Other history?
Prior Syphilis Hx:
7/2018: Syphilis EIA Ab+, RPR 1:64 
(asymptomatic)
8/2018: RPR 1:512-> Treated with Bicillin IM  x 
1 dose
9/23/19: Syphilis EIA Ab+, RPR NR, Particle 
Agglutination Reactive
Other history?
How would you treat him? (He has NKDA)
Follow up visit: 
He reports adherence to ART and denies 
missing any doses in the last month.  You 
decide to obtain repeat labs and follow up the 
next week.  Interim labs return:  
HIV VL:  82,400 CD4 776 (36%) 
RPR: 1:512
Does this change your treatment plan for 
syphilis?
How would you address his HIV? 
On exam you note mild bilateral upper extremity 
postural  tremor  and dysmetria.  His neuro 
exam is otherwise unremarkable.  He reports 
tremor has been present since hospitalization in 
May and preceded current rash. 
Syphilis Natural history
Non-treponemal Treponeme-Specific
Assays RPR (Rapid Plasma Reagin) 
VDRL (Venereal Disease 
Research Laboratory)
TPPA (T Pallidum Particle 
Agglutination) 
EIA (T Pallidum Enzyme 
Immunoassay) 
Ab Detected cardiolipin-cholesterol-lecithin ag recombinant treponemal antigen
Sensitivity (False neg) Poor in early infection
Long-standing w/ prolonged 
latency
Earlier seroconversion
Remains + after treatment or 
prolonged latency
Specificity (False +) Lower- need to confirm + with 
Treponemal test
Higher
Clinical Use: Initial test in lower prevalence 
areas (traditional seq)
Treatment response
Detecting re-infection in 
previously Tx’d patients
Initial screening test in higher 
prevalence areas (rev. seq)
Detection of early primary, old 
latent infections
Reverse Sequence Testing Algorithm
In what scenarios would 
negative testing warrant 
treatment?
➔ Exposure within 90 days 
to partner with confirmed 
active infection 
◆ retest 1,3 mo
➔ Skin lesion c/w primary 
syphilis
◆ Retest at 2-4 weeks 
if not treated
Treatment Algorithm
Syphilis Staging and Treatment:
Summary:
Primary, Secondary, early latent = 1 dose 
Penicillin
Late/Unknown Latent: 3 weekly doses
Neurosyphilis: 10-14 days IV
Treat with Penicillin whenever possible.  Only 
agent with good data in pregnancy, persons with 
HIV or neurosyphilis 
Monitoring Response to Treatment:
Follow up testing:
● Obtain repeat RPR w/ titer at 6&12 
months
● Consider 3,6,9,12 &24 if HIV+
● Should see 2 dilution (4-fold) decrease in 
titer
When to Worry about Treatment Failure:
● Persistent Si/sx after Tx
● Sustained 2+ week rise in titer (4 fold) s/p 
Tx
● Failure of RPR to decrease 4 fold in 6-12 
mo
How to address possible Treatment Failure:
● Rule out unrecognized HIV infection
● Evaluate for re-infection (by symptoms or 
exposures)
● Assess adherence if Tx’d w/ oral regimen
● Rule out neuro, ocular, otosyphilis
Retreat with 3 weekly doses of benzathine 
Penicillin G if no evidence of CNS infection
HIV and Syphilis:
● Interpretation of treponemal and nontreponemal testing the same
● Stage-based treatment is the same for those who are HIV negative
○ Penicillin alternatives not well studied in HIV+ individuals
● May have higher rates of serologic failure or “high serofast” state
● Higher risk for neurological complications in early (primary/secondary) 
infection
● CSF abnormalities associated with CD4 <350, RPR > 1:32
○ No clear indication for LP in the absence of neuro signs/sx
Is anyone paying attention? 
Syphilis Kahoots!
HIV Treatment 
He reports adherence to ART and denies 
missing any doses in the last month.  You 
decide to obtain repeat labs and follow up the 
next week.  Interim labs return:  
HIV VL:  82,400 
CD4 776 (36%) 
Prior HIV labs and treatment history:
HIV Dx 7/2018:  VL:  402,626, CD4 698 (26%)
Started on B/TAF/FTC (lost to care),
8/27/19: VL 21,159 (reported 2 week Tx lapse)
HIV genotype:  NRTI: no RAMs, NNRTI: 
E138A, PI: no RAMs,  INSTI: No RAMs
9/23/19: VL 124 CD4 696 (38%)
How can we promote ART adherence?
How would you address his viremia?
Linkage & Retention:
Adherence Strategies:
➔ • Regularly assess adherence to ART and appointments.
◆ Engage patients with a constructive,collaborative, nonjudgmental, and problem-solving approach
➔ Elicit an individual’s barriers to adherence:
◆ personal barriers (e.g., substance use, housing instability, stigma, lack of transportation)
◆ clinic barriers (e.g., limited clinic hours, processes that make it more difficult to obtain prescriptions or 
schedule appointments)
◆ system barriers (e.g. copays/assistance,PAT ,other Rx coverage/refill processes)
➔ Tailor ART to improve adherence: 
◆ Involve patient in treatment decisions/ART selection
◆ simplify dosing or reduce side effects
◆ Choose regimens without food requirements
◆ Choose ART regimen with high genetic barrier to resistance (dolutegravir (bictegravir), boosted-darunavir
◆ Consider out of pocket costs/copays
➔ Link patients to counseling to overcome stigma, substance use, or depression
➔ Multidisciplinary approaches and time to understand and address barriers are needed with help of social work and 
case management when available
HIV Treatment 
He reports adherence to ART and denies 
missing any doses in the last month.  You 
decide to obtain repeat labs and follow up the 
next week.  Interim labs return:  
HIV VL:  82,400 
CD4 776 (36%) 
Prior HIV labs and treatment history:
HIV Dx 7/2018:  VL:  402,626, CD4 698 (26%)
Started on B/TAF/FTC (lost to care),
8/27/19: VL 21,159 (reported 2 week Tx lapse)
HIV genotype:  NRTI: no RAMs, NNRTI: 
E138A, PI: no RAMs,  INSTI: No RAMs
9/23/19: VL 124 CD4 696 (38%)
How would you address his viremia?
ARV Viremia ?s
Terminology Review
Virologic suppression: A confirmed HIV RNA level below level of detection
Virologic failure: The inability to achieve or maintain suppression of viral replication to an 
HIV RNA level <200 copies/mL
Incomplete virologic response: Two HIV RNA levels ≥200 copies/mL after 24 weeks on an 
ARV regimen w/o documented suppression
Virologic rebound: Confirmed HIV RNA ≥200 copies/mL after virologic suppression
Virologic blip: After virologic suppression, an isolated detectable HIV RNA level that is 
followed by a return to virologic suppression
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 
Department of Health and Human Services
Potential Causes of Viremia:
● Suboptimal adherence
● Viral blip
● Drug resistance:
■ Inherited/Transmitted
■ Acquired
● Suboptimal adherence
● Rx-Rx or Food-Rx interactions
Addressing Detectable Viral Load: Clinical Situations
● HIV RNA above the LLOD and <200 copies/mL. Confirm VL and assess adherence, drug-drug  and drug-food 
interactions. 
a. Viral blip does not require change in treatment(AII)
b. Persistent viremia <200 copies/mL- risk of resistance low but requires closer monitoring (AIII)
● HIV RNA ≥200 and <1,000 copies/mL. Confirm VL and assess as per above
a. Persistently >200 copies/mL- higher risk of resistance
b. If confirmatory VL > 1000 copies/mL- obtain resistance testing (consider if >500)
● HIV RNA >1,000 copies/mL and no drug resistance identified.
a. Patient is likely not taking meds - confirm timing of test relative to patient stopping meds
b. If the current regimen is well tolerated- restart old regimen- repeat VL 2-4 weeks after restarting and if VL >500 
get resistance testing
● HIV RNA >1,000 copies/mL and drug resistance identified. 
a. Change ART regimen
Case 2:  JW 51yo M presents for f/u of HIV and 
chronic conditions
He takes the following medications:
HIV: Elvitegravir/cobicistat/tenofovir AF/Emtricitabine (Genvoya)
Mod-persistant Asthma/Allergy:  albuterol HFA, montelukast 10mg, fluticasone 
furoate/vilanterol (Breo) 200mcg/25mcg, Fluticasone prop. nasal
DM2: glipizide XL 20mg daily, Metformin XR 750mg BID, januvia 100mg daily
HTN/HL: lisinopril 10mg daily, chlorthalidone 25mg daily atorvastatin 40mg daily
GERD: Omeprazole 40mg daily
Case 2:  JW 51yo M presents for f/u of HIV and 
chronic conditions
He obtained the Following labs prior to his visit:
HIV VL <40, CD4 1165 (44%)
HbA1c: 9.2%
Cr: 1.4 (eGFR 45)
LDL 51, TG 81, HDL 59 (ASCVD 20%)
He is reluctant to start insulin or other injectable medications for DM. How can we 
optimize his regimen?
Moore Kahoots!
ARVs and Glucocorticoids
https://www.hiv-
druginteractions.org/drug_queries/472812/drug_query_interactions/table_view
Medication Interactions
http://www.hiv-druginteractions.org
Statins and PK inhibitors
● Most PIs (and boosted INSTI)  inhibit the metabolism of most statins
● Increased risk of toxicity 
● Simvastatin and Lovastatin have the most interactions
● Fluvastatin and Pitavastatin have a safer profile
● Atorvastatin had the most data with Darunavir/r - need to dose adjust
ARV and GERD Treatments
Food-Drug Interactions
● No Food Requirement:
○ Bictegravir,Dolutegravir or 
Raltegravir- based regimens 
(INSTI)
● Take with Food:
○ Atazanavir/r, Darunavir/r 
(PI)
○ Elvitegravir based regimen 
(INSTI)
○ Rilpivirine (NNRTI)
● Take without food:
○ Efavirenz (NNRTI)
Note on Rilpivirine (RPV):
● Requires acid for adequate 
absorption 
○ Requires >390 kcal meal
○ Contraindicated with PPIs 
○ Separate  H2 or antacids 
HCV Case- RS
63yo M Hx of chronic HCV, Seizure d/o, Latent 
TB (untreated), DM2, GERD, HTN, CKD and 
remote CVA presents for routine follow up.
Hx of chronic HCV first Dx’d in 2015.  Tx naive. 
Remote hx of IDU.
Current meds: Amlodipine 5 mg,  keppra 1500 
mg TID.  Valproic acid 750 MG  BID, 
Atorvastatin 40mg, Pantoprazole 40mg daily
How would you evaluate him for treatment?
Labs/Studies:
HCV PCR: 5,290,000 copies/mL
Genotype: 1b, NS5a resistance not predicted
HIV Ab/Ag: NR
HbsAg: NR, HbsAb: NR, HbcAb: Reactive
HepA IgG,IgM: NR
Hgb 11.9, Plt 295
AST: 39, ALT 34, ALP 57, Tbil 0.4, Alb 4.3
Elastography: Median liver stiffness 6.59 kPa, mod risk 
of clinically significant fibrosis (F2-F3), hepatic steatosis
Steps before treatment HCV Ab+ patients:
1) Are they infected? Get HCV PCR
2) Have they been treated before?
3) Do they have Cirrhosis?:
a) ***Calculate FIB-4 score. >3.25 OR
b) ***Transient elastography indicating cirrhosis (eg, 
FibroScan stiffness >12.5 kPa)
c) Noninvasive serologic tests above cutoffs (eg, 
FibroSure, Enhanced Liver Fibrosis Test, etc)
d) Clinical evidence of cirrhosis (eg, liver nodularity 
and/or splenomegaly on imaging, platelet count 
<150,000/mm3)
e) Prior liver biopsy showing cirrhosis
4) If yes, is it decompensated?: 
a) Calculate CTP score: ≥ 7 or ascites, 
encephalopathy, Tbili≥2, INR≥1.7, Albumin <3.5 -> 
If yes then refer
5) Is there evidence of HCC? Eval with US
6) Medication reconciliation & review interactions:
a) AASLD/IDSA guidance
b) Liverpool drug interaction checker.
c) Pretreatment laboratory testing:
7) Do they have HIV? Order Ab/Ag test
8) Do they have chronic hep B? Order HbSAg
9) Get additional Labs (if needed)
a) Complete blood count (CBC)
b) Hepatic function panel
c) eGFR (Cr)
10) Are they or can they get pregnant? Pregnancy Test & 
counsel
Treatment of HCV
1) Glecaprevir (300 mg) / pibrentasvir (120 mg) (Mavyret) for 8 
weeks
a) Needs to be taken with food
b) PI raises potential for Rx-Rx interactions
c) 3 tablets daily
2) Sofosbuvir (400 mg) / velpatasvir (100 mg) (Epclusa) for  12 
weeks
a) In compensated cirrhosis need NS5A resistance 
testing for genotype 3
b) Single tablet
Be mindful of Rx interactions:
➔ Statins
➔ PPI, H2RA, Antacids
➔ Anticoagulants
➔ Antiepileptics
➔ Hypoglycemic drugs
Treatment monitoring:
➔ Assess adherence and treatment side effects
➔ Monitor hypoglycemia in diabetic patients
➔ INR if on warfarin
➔ Cirrhosis: consider LFTs in patients 
Post-treatment evaluation:
➔ Confirm SVR-12 with HCV PCR 12 weeks 
after treatment along with LFTs
➔ Assess reinfection risk
➔ Limit/avoid ETOH
➔ Cirrhosis: HCC screening w/ US q6mo, 
variceal screening with EGD q2-3yr 
HCV Kahoots
Resources
DHHS: https://aidsinfo.nih.gov/
IAS-USA: https://www.iasusa.org/
Ward 86 :https://hiv.ucsf.edu/education/recommendations.html
Liverpool HIV interactions: http://www.hiv-druginteractions.org/
Liverpool HCV interactions: https://www.hep-druginteractions.org/
HIV and Aging: http://hiv-age.org/
Stanford University HIV Resistance Database: http://hivdb.stanford.edu
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